<SUBMISSION>
<ACCESSION-NUMBER>0001144204-03-005739
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>2
<PERIOD>20030922
<ITEMS>5
<ITEMS>7
<FILING-DATE>20030922
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>ADVANCED BIOTHERAPY INC
<CIK>0000791833
<ASSIGNED-SIC>8731
<IRS-NUMBER>510402415
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-26323
<FILM-NUMBER>03904423
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>6355 TOPANGA CANYON BLVD
<STREET2>SUITE 510
<CITY>WOODLAND HILLS
<STATE>CA
<ZIP>91367
<PHONE>8188833956
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>6355 TOPANGA CANYON BLVD
<STREET2>SUITE 510
<CITY>WOODLAND HILLS
<STATE>CA
<ZIP>91367
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>ADVANCED BIOTHERAPY CONCEPTS INC
<DATE-CHANGED>19990524
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.txt
<TEXT>
                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest reported)  September 22, 2003
                                           --------------------


                            Advanced Biotherapy, Inc.
                           --------------------------
             (Exact name of registrant as specified in its charter)

          Delaware                    0-26323                51-0402415
     ------------------             ------------         ---------------------
 (State or other jurisdiction       (Commission           (IRS Employer
       of incorporation)            File Number)           Identification No.)

6355 Topanga Canyon Boulevard, Suite 510                            91367
----------------------------------------                            -----
Woodland Hills, California                                       (Zip Code)
--------------------------
(Address of principal executive offices)

Registrant's telephone number, including area code   (818) 883-6716
                                                   --------------------


<PAGE>


Item 5.  OTHER EVENTS.

         The registrant published a press release on September 19, 2003 which
reported the results of its sponsored investigational clinical studies in
treating children suffering from Type 1 Diabetes (an autoimmune disease) and
Juvenile Rheumatoid Arthritis-Associated Ureitis (an autoimmune disease) at the
8th International Workshop on Autoantibodies and Autoimmunity in Berlin, Germany
last week.

Item 7.  FINANCIAL STATEMENTS AND EXHIBITS

(c) Exhibits.

Designation       Description of Exhibit


99.1              Press Release, dated September 19, 2003


                                   Signatures

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                    ADVANCED BIOTHERAPY, INC.
                                    (Registrant)


Date:  September 19, 2003           By: /s/Edmond Buccellato
                                        -------------------------------------
                                        Edmond Buccellato, President and CEO




                                INDEX TO EXHIBITS

      Exhibit        Description
      -------        -----------


      99.1           Text of Press Release, dated September 19, 2003




</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>ex-99_1.txt
<TEXT>



LOS ANGELES--(BUSINESS WIRE)--Sept. 19, 2003--

Scientists Report Encouraging Results in
Treating Children with Type 1 Diabetes

Advanced Biotherapy Inc. (OTCBB:ADVB) -- a developer of pioneering antibody
therapies for treating severe and widespread autoimmune diseases -- reported the
results of its sponsored investigational clinical studies in treating children
suffering from Type 1 Diabetes (an autoimmune disease) at the "8th International
Workshop on Autoantibodies and Autoimmunity" in Berlin, Germany last week.
Results of this study indicated that all patients were able to reduce their
daily insulin dose after a short course of therapy.

Mr. Edmond Buccellato, the Company's CEO, stated, "Type 1 diabetic children were
treated at the Research Institute of Pediatric Hematology of Russia with a short
course of our investigational antibodies to interferon gamma with each patient
observed and evaluated for a follow-up period of 10-12 months. Mean C-peptide
(an indicator of insulin production) rose, the C-peptide/glycemia ratio
increased, and each patient's normally required insulin dose was dropped
significantly, all indicators of positive clinical and laboratory effects. One
child was also afflicted with the autoimmune condition psoriasis vulgaris.
Significant improvement was also observed in that condition, and remission
continued through the follow-up period. This study supports the view that use of
anti-interferon-gamma therapy, protected under our intellectual property, can
promote remission of Type 1 diabetes. The reported results aroused strong
enthusiasm from participants at the conference."

Type 1 diabetes is a condition characterized by high blood glucose levels caused
by a lack of insulin that occurs when the body's immune system attacks and
destroys the insulin-producing beta cells in the pancreas. The pancreas then
produces little or no insulin. Type 1 diabetes develops most often in young
people but can appear in adults. In the U.S. alone, there are approximately 1.7
million people suffering from Type 1 diabetes, a number which is growing.

Mr. Buccellato further commented, "Our principal investigators were also asked
by the conference to present results from the Company sponsored investigational
studies in patients suffering from Juvenile Rheumatoid Arthritis-Associated
Uveitis. As reported during the conference, children suffering from this disease
who had been treated with standard immunosuppressant therapy were also treated
with a short course of antibodies to interferon-gamma in combination with
standard therapy. For those patients treated with anti-interferon gamma combined
with standard therapy, exacerbation of the disease was halted more quickly and
remission continued longer than with standard therapy alone. The use of
antibodies to interferon-gamma for this disease is also protected under our
intellectual property."


<PAGE>

Uveitis is a condition characterized by inflammation inside the eye,
specifically affecting one or more of the three parts of the eye that make up
the uvea: the iris (the colored part of the eye), the ciliary body (behind the
iris, responsible for manufacturing the fluid inside the eye), and the choroid
(the vascular lining tissue underneath the retina). Uveitis is the third leading
cause of blindness in the United States, after diabetes and macular
degeneration.

Autoimmune diseases in general are the result of an inappropriate immune
response in which the body's immune system attacks its own healthy cells and
organs. In these disorders, certain chemicals called cytokines are
hyperproduced, and bring about the autoimmune condition. One of the company's
patented therapies is designed to remove or neutralize these excessive cytokines
known as interferon-gamma and tumor necrosis factor-alpha, which is induced by
interferon-gamma. Removal of these agents is associated with beneficial
therapeutic effects and could possibly form the basis of a universal treatment
for certain types of autoimmune diseases. Advanced Biotherapy has already
achieved encouraging results in clinical trials in rheumatoid arthritis,
multiple sclerosis, various autoimmune skin diseases (psoriasis, alopecia
areata, vitiligo, pemphigus, epidermolysis bullosa), and others.

About Advanced Biotherapy

Advanced Biotherapy, Inc. is pioneering the development of new antibody
therapies for treating severe and widespread autoimmune diseases. Its
investigational therapies attack autoimmune diseases at their source,
neutralizing biologic imbalances that impair immune-system function.
Core technology is protected under U.S. patents and patents pending for
the exclusive use of a class of antibodies to the protein known as
interferon-gamma and to tumor necrosis factor-alpha for treating a range
of diseases. The company is headquartered in Los Angeles.
www.advancedbiotherapy.com

Statements made in this news release, other than statements of historical fact,
are forward-looking statements and are subject to a number of uncertainties that
could cause actual results to differ materially from the anticipated results or
other expectations expressed in our forward-looking statements. The risks and
uncertainties which may affect the development, operations and results of our
business include, but are not limited to the following: risks associated with

<PAGE>

clinical trials, the uncertainties of research and product development programs,
the uncertainties of the regulatory approval process, the risks of competitive
products, the risks of our current capital resources, the uncertainties as to
the availability of future capital and our future capital requirements, and the
risks associated with the extent and breadth of the Company's patent portfolio.
The foregoing discussion of the pending clinical investigations and the effect
of the patents issued and pending involves risks and uncertainties, including
but not limited to the risks that third parties may be successful in challenging
such patents; or that granted claims may be held invalid or interpreted
differently by a court of law; or that new technologies will be developed that
are superior in treating the diseases targeted by Advanced Biotherapy, Inc.
Readers are cautioned not to place reliance on these forward-looking statements,
which speak only as of the date the statements were made. See the Company's
public filings with the Securities and Exchange Commission for further
information about risks and uncertainties that may affect the Company and the
results or expectations expressed in our forward-looking statements, including
the section captioned "Factors That May Affect The Company" contained in the
Company's Annual Report on Form 10-KSB for the fiscal year ended December 31,
2002.

CONTACT:

Advanced Biotherapy, Inc.

Amy Buccellato, 818-883-6716

www.advancedbiotherapy.com

SOURCE: Advanced Biotherapy, Inc.


</TEXT>
</DOCUMENT>
</SUBMISSION>
